专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009009793A2 INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY 审中-公开
标题翻译： AKT / PKB抑制剂具有抗肿瘤活性
公开(公告)号：WO2009009793A2
公开(公告)日：2009-01-15
申请号：PCT/US2008069974
申请日：2008-07-14
申请人： UNIV SOUTH FLORIDA , CHENG JIN Q , SUN MEI , SEBTI SAID M
发明人： CHENG JIN Q , SUN MEI , SEBTI SAID M
IPC分类号： A61K31/517 , A61K31/13 , A61K31/53
CPC分类号： C07D471/04 , C07H19/23
摘要： The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering an effective amount of a compound of formula I to the person or animal.
摘要翻译：本发明涉及用于抑制Akt / PKB途径的材料和方法。在一个实施方案中，本发明化合物抑制Akt蛋白的激酶活性和/或磷酸化水平。本发明还涉及用于抑制或杀死其中Akt蛋白的表达升高或组成性活性的癌细胞或其他细胞的方法，包括使细胞与有效量的式I化合物接触。本发明还涉及方法用于治疗人或动物中的癌症或肿瘤，所述方法包括给予人或动物有效量的式I化合物。

2. 发明申请

WO2005094322A3 EFFECTIVE TREATMENT OF TUMORS AND CANCER WITH TRICIRIBINE AND RELATED COMPOUNDS 审中-公开
标题翻译：有效治疗肿瘤和癌症与相关化合物及相关化合物
公开(公告)号：WO2005094322A3
公开(公告)日：2005-12-29
申请号：PCT/US2005010422
申请日：2005-03-29
申请人： UNIV SOUTH FLORIDA , CHENG JIN Q , SEBTI SAID M
发明人： CHENG JIN Q , SEBTI SAID M
IPC分类号： A61K31/70 , A61K31/7076 , C07H19/02
CPC分类号： C07H17/02 , A61K31/7064
摘要： The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
摘要翻译：发明人已经确定，与现有技术和经验相反，如何成功地使用三苯呋嗪治疗肿瘤和癌症，其中一种或其组合（i）仅根据下述诊断试验给患者施用三苯呋嗪，表现出对毒品; （ii）使用使药物的毒性最小化但仍显示功效的所述剂量水平; 或（iii）使用最小化药物的毒性的所述剂量方案。

3. 发明申请

WO2008070823A2 SUBSTRATE-MIMETIC AKT INHIBITOR 审中-公开
标题翻译：基质 - 模拟AKT抑制剂
公开(公告)号：WO2008070823A2
公开(公告)日：2008-06-12
申请号：PCT/US2007086751
申请日：2007-12-07
申请人： UNIV SOUTH FLORIDA , UNIV YALE , SEBTI SAID M , CHENG JIN Q , HAMILTON ANDREW D , KAYSER KATHERINE
发明人： SEBTI SAID M , CHENG JIN Q , HAMILTON ANDREW D , KAYSER KATHERINE
IPC分类号： A61K38/08
CPC分类号： C12N9/12 , A61K31/132 , A61K31/404 , A61K38/00 , C07C255/50 , C07C255/51 , C07C255/60 , C07C279/12 , C07C2601/16 , C07D209/04 , C07D209/14 , C07K5/02 , C07K5/0207 , C07K5/06 , C07K5/08 , C07K5/10 , C07K7/02 , C07K7/06 , C12N9/1205 , C12Y207/11001
摘要： Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.
摘要翻译：本文公开了一种致癌蛋白Akt的肽和非肽抑制剂。从Akt靶底物GSK-3的残基开始，表征GSK-3残基的功能结构域。功能上同源的非肽基团取代了GSK-3的氨基酸，形成了能够结合Akt的杂合肽 - 非肽和非肽化合物。与肽对应物相比，非肽化合物显示增加的稳定性和刚性，并且不易降解。与基于肽的Akt抑制剂类似，结合的非肽化合物对Akt表现出抑制作用。

4. 发明申请

WO2008094321A2 AKT SENSITIZATION OF CANCER CELLS 审中-公开
标题翻译： AKT对癌细胞的敏感性
公开(公告)号：WO2008094321A2
公开(公告)日：2008-08-07
申请号：PCT/US2007080441
申请日：2007-10-04
申请人： UNIVERSTIY OF SOUTH FLORIDA , SEBTI SAID M , CHENG JIN Q
发明人： SEBTI SAID M , CHENG JIN Q
CPC分类号： C07K16/32 , A61K39/39558 , A61K45/06 , C07K2317/24 , A61K2300/00
摘要： Most human tumors find ways to resist anticancer drug monotherapy. Akt is considered a likely peptide providing such monotherapy drug resistance. Data indicates that Akt chemoresistance is induced in a p53-dependent manner and that inhibition of Akt may be an effective means of overcoming chemoresistance in cancer cells expressing wild-type p53. Breast, ovarian, lung cancer and leukemia cells lines were treated with combinations of Akt activation inhibitor Triciribine (TCN) or Triciribine phosphate (TCNP) and chemotherapeutic drugs to determine the efficiency of combination therapy. Additionally, cells were introduced into xenograft models to determine in vivo effects of combination treatment. Combining TCN or TCNP with other anticancer drugs overcame cytotoxic or treatment resistance. Thus, TCN and TCNP are shown to broaden the spectrum of human tumors that can be effectively treated.
摘要翻译：大多数人类肿瘤都能找到抵抗抗癌药物单药治疗的方法。 Akt被认为是提供这种单一疗法药物抗性的可能肽。数据表明Akt化学抗性是以p53依赖性方式诱导的，并且抑制Akt可能是克服表达野生型p53的癌细胞中化学抗性的有效手段。用Akt激活抑制剂Triciribine（TCN）或Triciribine phosphate（TCNP）与化疗药物联合治疗乳腺癌，卵巢癌，肺癌和白血病细胞系以确定联合疗法的效率。另外，将细胞引入异种移植模型以确定组合治疗的体内效应。将TCN或TCNP与其他抗癌药物组合克服了细胞毒性或治疗抗性。因此，TCN和TCNP被证明可以拓宽可以有效治疗的人类肿瘤的范围。

5. 发明申请

WO2008060581A2 COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF 审中-公开
标题翻译：包括TRICUIBA和TRASTUZUMAB的组合物及其使用方法
公开(公告)号：WO2008060581A2
公开(公告)日：2008-05-22
申请号：PCT/US2007023963
申请日：2007-11-15
申请人： CLEVELAND CLINIC FOUNDATION , GREENLEAF DANIEL , AKINSANMI LAWRENCE , CHENG JIN Q , SEBTI SAID M
发明人： GREENLEAF DANIEL , AKINSANMI LAWRENCE , CHENG JIN Q , SEBTI SAID M
CPC分类号： A61K31/7064 , A61K39/395 , A61K39/39558 , A61K2300/00
摘要： This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell roliferation.
摘要翻译：本申请涉及组合疗法，包括三苯呋嗪和相关化合物以及曲妥珠单抗或其盐以及对治疗和预防与异常细胞增殖有关的肿瘤，癌症和其它病症的毒性降低的组合物。

6. 发明申请

WO2005110477A3 COMBINATION THERAPIES FOR CANCER AND PROLIFERATIVE ANGIOPATHIES 审中-公开
标题翻译：癌症和增殖性血管病的组合治疗
公开(公告)号：WO2005110477A3
公开(公告)日：2006-03-09
申请号：PCT/US2005012081
申请日：2005-04-08
申请人： UNIV SOUTH FLORIDA , YU HUA E , JOVE RICHARD , CHENG JIN Q , SEBTI SAID , NIU GUILIAN
发明人： YU HUA E , JOVE RICHARD , CHENG JIN Q , SEBTI SAID , NIU GUILIAN
IPC分类号： A61K31/282 , A61K31/7064 , A61K39/395 , A61K45/00 , A61K45/06 , A61P35/00
CPC分类号： C12N15/1135 , A61K31/282 , A61K31/7064 , A61K39/395 , A61K45/06 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2320/31 , A61K2300/00
摘要： Compositions and methods for treating cancer and proliferative angiopathies are provided. A composition can include an inhibitor of the Jak2/Stat3 signaling pathway and an inhibitor of the PI3k/Akt signaling pathway. In certain cases, the two inhibitors are capable of acting synergistically as compared to either inhibitor alone.
摘要翻译：提供了治疗癌症和增殖性血管病的组合物和方法。组合物可以包括Jak2 / Stat3信号通路的抑制剂和PI3k / Akt信号通路的抑制剂。在某些情况下，与单独的抑制剂相比，两种抑制剂能够协同作用。

7. 发明公开

EP1737472A4 EFFECTIVE TREATMENT OF TUMORS AND CANCER WITH TRICIRIBINE AND RELATED COMPOUNDS 有权
标题翻译： WIRKSAME BEHANDLUNG VON TUMOREN UND KREBS MIT TRICIRIBIN UND VERWANDTEN VERBINDUNGEN
公开(公告)号：EP1737472A4
公开(公告)日：2010-09-01
申请号：EP05746910
申请日：2005-03-29
申请人： UNIV SOUTH FLORIDA
发明人： CHENG JIN Q , SEBTI SAID M
IPC分类号： A61K31/70 , A61K31/7064 , A61K31/7076 , A61P35/00 , C07H19/02
CPC分类号： C07H17/02 , A61K31/7064

8. 发明公开

EP2173352A4 INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY 失效
标题翻译： AKT /具有抗肿瘤效果PKB的抑制剂
公开(公告)号：EP2173352A4
公开(公告)日：2011-07-27
申请号：EP08772544
申请日：2008-07-14
申请人： UNIV SOUTH FLORIDA
发明人： CHENG JIN Q , SUN MEI , SEBTI SAID M
IPC分类号： C07D471/04 , A61K31/519 , A61K31/7068 , A61P35/00 , C07H19/23
CPC分类号： C07D471/04 , C07H19/23

9. 发明申请

WO2008070100A8 COMPOSITIONS INCLUDING TRICIRIBINE AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR COMPOUNDS OR SALTS THEREOF AND METHODS OF USE THEREOF 审中-公开
标题翻译：包括特异性和生殖因子生长因子受体抑制剂化合物或其盐的组合物及其使用方法
公开(公告)号：WO2008070100A8
公开(公告)日：2008-08-14
申请号：PCT/US2007024873
申请日：2007-12-05
申请人： UNIV SOUTH FLORIDA
发明人： CHENG JIN Q , SEBTI SAID M
IPC分类号： A61K31/517 , A61K31/7064 , A61P35/00
CPC分类号： A61K31/517 , A61K31/7064 , A61K45/06 , A61K2300/00
摘要： This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
摘要翻译：本申请涉及组合疗法，包括三叉二烯化合物和表皮生长因子受体抑制剂化合物，特别是厄洛替尼类化合物和对治疗和预防肿瘤，癌症以及与异常细胞增殖相关的其它病症的毒性降低的组合物。

10. 发明专利

MX2010000474A INHIBIDORES DE PROTEINA SERINA/TREONINA QUINASA A/PROTEINA QUINASA B CON ACTIVIDAD ANTITUMORAL. 未知
公开(公告)号：MX2010000474A
公开(公告)日：2010-06-23
申请号：MX2010000474
申请日：2008-07-14
申请人： UNIV SOUTH FLORIDA
发明人： SEBTI SAID M , CHENG JIN Q , SUN MEI
IPC分类号： A61K31/517 , A61K31/136 , A61K31/53 , C07D211/00 , C07D239/70
摘要： La invención se refiere a materiales y métodos para inhibir la vía Akt/PKB; en una modalidad, un compuesto de la invención inhibe la actividad de quinasa y/o los niveles de fosforilación de las proteínas Akt; la invención también se refiere a métodos para inhibir o eliminar una célula cancerosa u otra célula en la que la expresión de una proteína Akt esta elevada o constitutivamente activa, que comprende poner en contacto la célula con una cantidad efectiva de un compuesto de fórmula I; la invención también se refiere a métodos para tratar cáncer o un tumor en una persona o animal que comprende administrar una cantidad efectiva de un compuesto de fórmula I a la persona o animal.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式